SC 13D/A 1 tm213823d1_sc13da.htm SC 13D/A

 

  

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549    

         

SCHEDULE 13D

 

Under the Securities Exchange Act of 1934
(Amendment No. 5)*

 

Intellia Therapeutics, Inc.

(Name of Issuer)

 

COMMON STOCK, PAR VALUE $0.0001 PER SHARE

(Title of Class of Securities)

 

45826J105

(CUSIP Number)

 

Scott A. Brown
General Counsel and
Chief Administrative Officer
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, MA 02139
(617) 871-8000
 

With a copy to:

 

G. Scott Lesmes, Esq.

Hillary P. Daniels, Esq.
Morrison & Foerster LLP
2000 Pennsylvania Avenue NW, Suite 6000
Washington, D.C. 20006
(202) 887-1500

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

 

January 21, 2021

(Date of Event Which Requires Filing of this Statement)
 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-l(f) or 240.13d-l(g), check the following box. ¨

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

  

CUSIP No. 45826J105 

 
      1.     Names of Reporting Persons
 Novartis Institutes for BioMedical Research, Inc.  
     
 
    2.   

Check the Appropriate Box if a Member of a Group (See Instructions)   

 

        (a)    o  
       
        (b)    o  
       
 
    3.  

SEC Use Only  

 

     
    4.   Source of Funds (See Instructions)
 WC  
     
 
    5.  

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)  o  

 

 
  6.    

Citizenship or Place of Organization
 Delaware  

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With    		 7.    

Sole Voting Power
 None  

 

 
8.    

Shared Voting Power
2,176,148 

 

 
9.    

Sole Dispositive Power
 None  

 

 
10.    

Shared Dispositive Power
2,176,148

 

 
      11.  

Aggregate Amount Beneficially Owned by Each Reporting Person
2,176,148 

 

 
    12.  

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) o  

 

 
      13.  

Percent of Class Represented by Amount in Row (11)
3.7%*  

 

 
      14.    

Type of Reporting Person (See Instructions)
 CO  

 

           

 

* This calculation is based on 59,080,783 shares of common stock, par value $0.0001 per share (“Common Stock”), outstanding as of October 30, 2020, as reported by the Issuer on its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020, filed by the Issuer with the Securities and Exchange Commission (“SEC”) on November 5, 2020.

 

2

 

 

CUSIP No. 45826J105    
     
      1.    

Names of Reporting Persons
 Novartis AG

 

     
      2.    

Check the Appropriate Box if a Member of a Group (See Instructions)

 

        (a)  

¨

 

        (b)  

¨

 

     
      3.    

SEC Use Only

 

     
      4.    

Source of Funds (See Instructions)
 AF

 

     
      5.    

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨

 

     
      6.     Citizenship or Place of Organization
 Switzerland    

 

     
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With    		 7.    

Sole Voting Power
 None

 

     
8.     Shared Voting Power
2,176,148    
     
9.    

Sole Dispositive Power
 None

 

     
10.     Shared Dispositive Power
2,176,148    
     
      11.    

Aggregate Amount Beneficially Owned by Each Reporting Person
2,176,148

 

     
      12.    

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨

 

     
      13.    

Percent of Class Represented by Amount in Row (11)
3.7%*

 

     
      14.    

Type of Reporting Person (See Instructions)
 CO, HC

 

           

 

 

 

* This calculation is based on 59,080,783 shares of Common Stock, outstanding as of October 30, 2020, as reported by the Issuer on its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020, filed by the Issuer with the SEC on November 5, 2020.

 

3

 

 

Explanatory Note

 

This Amendment No. 5 (the “Amendment No. 5”) amends the statement on Schedule 13D originally filed by the Reporting Persons on May 11, 2016 and amended on December 14, 2017, March 23, 2018, March 30, 2020 and August 20, 2020 (the “Schedule 13D”). The Items below amend the information disclosed under the corresponding Items of the Schedule 13D as described below. Except as specifically provided herein, this Amendment No. 5 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used but not defined herein shall have the meanings attributed to them in the Schedule 13D.

 

Item 2. Identity and Background

 

Item 2 of the Schedule 13D is hereby amended such that all references to Schedule I contained within Item 2 and otherwise within the Schedule 13D shall refer to the Schedule I included in this Amendment No. 5.

 

Item 5. Interest in Securities of the Issuer

 

Item 5 of the Schedule 13D is hereby amended and restated in its entirety to read as follows:

 

“(a)-(b) As of the date hereof, each of the Reporting Persons may be deemed, for purposes of Rule 13d-3 of the Act, directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of 2,176,148 shares of Common Stock. Each Reporting Person has shared voting and dispositive power with the other Reporting Person.

 

Based on the 59,080,783 shares of Common Stock outstanding as of October 30, 2020, as reported by the Issuer on its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020, filed by the Issuer with the SEC on November 5, 2020, the Common Stock held by the Reporting Persons constitutes 3.7% of the outstanding shares of Common Stock of the Issuer.

 

NIBRI is a wholly-owned indirect subsidiary of Novartis. Novartis, as the parent company of NIBRI, may be deemed to beneficially own all of the shares of Common Stock held directly by NIBRI.

 

(c) The price per share, exclusive of any fees, commissions or other expenses for the sales made by the Reporting Persons in the past 60 days are as set forth in the following table:

 

 

Reporting Person Sale Date Shares Sold Weighted Average Price Per Share Price Range for Shares Sold
NIBRI 1/19/21 185,914 $83.56 $81.86 to $85.09
NIBRI 1/20/21 107,814 $82.64 $80.52 to $85.46
NIBRI 1/21/21 1,882,419 $67.97 $67.51 to $82.51

 

4

 

 

The Reporting Persons undertake to provide the Issuer, any stockholder of the Issuer, or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Item 5(c) to this Schedule 13D.

 

The shares were sold in ordinary brokers’ transactions. Except as reported in this Item 5, none of the Reporting Persons has effected a transaction in shares of the Issuer’s common stock during the past 60 days.

 

(d) Not applicable.

 

(e) January 21, 2021.''

 

5

 

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Pursuant to Rule 13d-1(k)(1)(iii) of Regulation 13D-G of the General Rules and Regulations of the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached statement is filed on behalf of each of them.

 

Dated: January 22, 2021

 

    NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.  
           
    By:   /s/ Scott A. Brown
        Name:  Scott A. Brown  
       
        Title:  Authorized Signatory  
       
    NOVARTIS AG  
       
    By:   /s/ Christian Rehm
        Name:   Christian Rehm
       
        Title:   Authorized Signatory  
               
    By:   /s/ Lukas Foertsch
        Name:   Lukas Foertsch
       
        Title:   Authorized Signatory  

 

6

 

 

 

Schedule I

 

DIRECTORS AND EXECUTIVE OFFICERS OF

NOVARTIS AG AND NOVARTIS INSTITUTES FOR BIOMEDICAL
RESEARCH, INC.

 

DIRECTORS AND EXECUTIVE OFFICERS OF NOVARTIS AG

 

The name, function, citizenship and present principal occupation or employment of each of the directors and executive officers of Novartis AG are set forth below. Unless otherwise indicated below, (i) each occupation set forth opposite an individual’s name refers to employment with Novartis AG and (ii) the business address of each director and executive officer of Novartis AG is Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland.

 

Name    Relationship to
Novartis AG		    Present Principal Occupation  Citizenship 
Joerg Reinhardt, Ph.D.    Chairman of the Board of Directors    Chairman of the Board of Directors  German 
              
Enrico Vanni, Ph.D.    Vice Chairman of the Board of Directors    Independent Director  Swiss 
              
Nancy C. Andrews, M.D., Ph.D.    Director    Dean emerita, vice chancellor emerita for academic affairs, Duke University School of Medicine, US; Nanaline H. Duke Professor of Pediatrics, pharmacology and cancer biology, Duke University, US  American/Swiss 
              
Ton Buechner    Director    Independent Director  Dutch/Swiss
              
Patrice Bula    Director    Executive vice president and head of strategic business units, marketing, sales, and Nespresso, Nestlé SA, Switzerland  Swiss 

 

 

 

 

Srikant Datar, Ph.D.   Director      Dean of the Faculty and George F. Baker Professor of Administration, Harvard Business School, US  American
            
Elizabeth (Liz) Doherty   Director   Independent Director  British
            
Ann Fudge   Director      Independent Director  American
            
Bridgette Heller   Director   Co-founder and Chief Executive Officer, Shirley Proctor Puller Foundation, US  American
            
Frans van Houten   Director      Chief Executive Officer and chairman of the executive committee and the board of management, Royal Philips NV, Netherlands  Dutch
            
Simon Moroney   Director   Independent Director  German/New Zealander
            
Andreas von Planta, Ph.D.   Director      Senior Counsel, Lenz & Staehelin, Switzerland  Swiss
            
Charles L. Sawyers, M.D.   Director      Chair of the Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, US; Professor of Medicine and of Cell and Developmental Biology, Weill Cornell Graduate School of Medical Sciences, US  American

 

William T. Winters  Director  Chief Executive Officer and director of Standard Chartered PLC, UK  British, American

 

 

 

 

Vasant (Vas) Narasimhan, M.D.  Member of the Executive Committee; Chief Executive Officer  Member of the Executive Committee; Chief Executive Officer  American
          
Steven Baert  Member of the Executive Committee; Chief People and Organization Officer  Member of the Executive Committee; Chief People and Organization Officer  Belgian
          
Bertrand Bodson  Member of the Executive Committee; Chief Digital Officer  Member of the Executive Committee; Chief Digital Officer  Belgian
          
James (Jay) Bradner, M.D.  Member of the Executive Committee; President, Novartis Institutes for BioMedical Research  Member of the Executive Committee; President, Novartis Institutes for BioMedical Research  American
          
Harry Kirsch  Member of the Executive Committee; Chief Financial Officer  Member of the Executive Committee; Chief Financial Officer  German/Swiss
          
Shannon Thyme Klinger  Member of the Executive Committee; Chief Legal Officer  Member of the Executive Committee; Chief Legal Officer  American
          
Steffen Lang, Ph.D.  Member of the Executive Committee; Global Head of Novartis Technical Operations  Member of the Executive Committee; Global Head of Novartis Technical Operations  German/Swiss
          
Klaus Moosmayer, Ph.D.  Member of the Executive Committee; Chief Ethics, Risk and Compliance Officer  Member of the Executive Committee; Chief Ethics, Risk and Compliance Officer  German
          
Richard Saynor  Member of the Executive Committee; Chief Executive Officer, Sandoz  Member of the Executive Committee; Chief Executive Officer, Sandoz  British
          
Susanne Schaffert, Ph.D.  Member of the Executive Committee; President, Novartis Oncology  Member of the Executive Committee; President, Novartis Oncology  German

 

John Tsai, M.D.  Member of the Executive Committee; Head of Global Drug Development and Chief Medical Officer  Member of the Executive Committee; Head of Global Drug Development and Chief Medical Officer  American
          
Marie-France Tschudin     Member of the Executive Committee; President, Novartis Pharmaceuticals  Member of the Executive Committee; President, Novartis Pharmaceuticals   Swiss   
          
Robert Weltevreden  Member of the Executive Committee; Head of Novartis Business Services  Member of the Executive Committee; Head of Novartis Business Services  Dutch

 

 

 

 

DIRECTORS AND EXECUTIVE OFFICERS OF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

 

The name, function, citizenship and present principal occupation or employment of each of the directors and executive officers of Novartis Institutes for BioMedical Research, Inc. (“NIBR”) are set forth below. Unless otherwise indicated below, (i) each occupation set forth opposite an individual’s name refers to employment with Novartis Institutes for BioMedical Research, Inc. and (ii) the business address of each director and executive officer for Novartis Institutes for BioMedical Research, Inc. is 250 Massachusetts Avenue, Cambridge, MA 02139, USA.

 

Name

 

Relationship to Novartis Institutes
for BioMedical Research, Inc.

 

Present Principal
Occupation

 

Citizenship 

Joerg Reinhardt, Ph.D.  Chairman of the Board of Directors  Chairman of the Board of Directors, NIBR; Chairman of the Board of Directors; Novartis AG; Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland  German
          
Thomas Kendris  Director  President, Novartis Corporation; US Country President, Novartis Pharmaceuticals; Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland  American
          
Harry Kirsch  Director  Member of the Novartis AG Executive Committee; Chief Financial Officer, Novartis AG; Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland  German
          
James (Jay) Bradner, M.D.  Vice Chairman of the Board of Directors; President  Member of the Novartis AG Executive Committee; President of NIBR; Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland  American
          
Mark Borowsky  Chief Information Officer  Chief Information Officer, NIBR  American
          
Evan Beckman, M.D.  Global Head Translational Medicine  Global Head Translational Medicine, NIBR  American
          
Tewis Bouwmeester, Ph.D.  Head DAx, CBT, NIBR Site Head Switzerland  Head DAx, CBT, NIBR Site Head Switzerland, Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland  Netherlands
          
Karin Briner, Ph.D.  Head, Chemistry  Head, Chemistry, NIBR  Swiss
          
Julie McCarthy  Officer of NIBR  General Counsel and Vice President Legal, GNF  American

 

 

 

 

Scott Brown  Vice President and General Counsel; Chief Administrative Officer; Secretary  Vice President and General Counsel; Chief Administrative Officer; Secretary, NIBR  American
          
Christian Bruns, Ph.D.  Global Head, ATI  Global Head, ATI, Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland  German
          
Fenella Chisholm  Global Head People & Organization  Global Head People & Organization, NIBR  British
          
Stephen Cho, Ph.D.  Global Head, Portfolio Management  Global Head, Portfolio Management, NIBR  American
          
Shaun Coughlin  Global Head CVM  Global Head CVM, NIBR  American
          
Thierry Diagana, Ph.D.  Head NITD  Head NITD, One Health Plaza, East Hanover, NJ 07936  American
          
Christian Klee  Officer of NIBR  Country CFO USA and President, Novartis Corporation  American and Swiss
          
Glenn Dranoff, M.D.  Global Head, Exploratory Immuno-Oncology  Global Head, Exploratory Immuno-Oncology, NIBR  American
          
Jeffrey Engelman, M.D., Ph.D.  Oncology Disease Area Head  Oncology Disease Area Head, NIBR  American
          
Mairead Goetz  Global Head, NIBR SciOps  Global Head, NIBR SciOps  Irish
          
Philip Gotwals, Ph.D.  Global Head BD&L  Global Head BD&L, NIBR  American
          
Cynthia Grosskreutz, M.D., Ph.D.  Global Head Ophthalmology Diseases  Global Head Ophthalmology Diseases, NIBR  American
          
Gerald (Jerry) Joyce  Institute Director, GNF, Officer NIBR  Institute Director, GNF, Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121  American
          
Michaela Kneissel, Ph.D.  Global Head Musculoskeletal  Global Head Musculoskeletal, Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland  Austrian

 

 

 

 

XingLi Wang  Head of CNIBR  Head of GDD China, Novartis Shanghai Campus, 4218 Kinke Road, Pudong New Area, Shanghai, China 201203, CNIBR  American and Australian
          
Jeffrey Lockwood  Officer of NIBR  Head, Newsroom & Channel Management, NBS  American
          
Vishal Patel, Ph.D.  Chief of Staff  Chief of Staff, NIBR  American
          
Thomas Pietzonka, Dr. sc. nat  Global Head Biotherapeutic and Analytical Tech  Global Head Biotherapeutic and Analytical Tech, NIBR, Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland  Swiss
          
John Tallarico  Head Chemical Biology and Therapeutics  Head Chemical Biology and Therapeutics, NIBR  American
          
Jeffrey Porter  Officer of NIBR, Head CBT  Head Chemical Biology and Therapeutics, NIBR  American
          
Revathi Rammohan  Chief Financial Officer and Head of Research Operations; Treasurer  Chief Financial Officer and Head of Research Operations; Treasurer, NIBR  British
          
Dirk Schuebeler, Ph.D.  Senior Group Leader, Musculoskeletal, FMI  Director of  FMI, Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland  German
          
Alice Shaw, M.D., Ph.D.  Global Head Translational Clinical Oncology  Global Head Translational Clinical Oncology, NIBR  American
          
Jean Silveri  Global Head R&D IP  Global Head R&D IP, NIBR  American
          
Fiona Spence, Ph.D.  Global Head of Preclinical Safety  Global Head of Preclinical Safety, NIBR  United Kingdom
          
Vendana (Wendi) Yajnik, Ph.D.  Global Head of Academic Partnerships and External Innovation  Global Head of Academic Partnerships and External Innovation, NIBR  American

 

Haripriya (Priya) Mannan   Assistant Secretary NIBR Board   Executive Director and Associate General Counsel, NIBR   American
          
Patricia (Pat) Sestak  Assistant Treasurer NIBR Board  US Head of Tax & Insurance, Novartis Corporation  American
          
Rachel Morgan  Officer of NIBR  Global Head of Clinical Science and Innovations, NIBR  British